Pre Seed · Biotech · Geneva, Switzerland · Founded 2016 · 9–19 employees
GliaPharm is a Swiss biotech developing breakthrough treatments for neurological disorders by targeting glial cells to restore brain energy metabolism. Founded in 2016 as an EPFL spinoff, the company focuses on conditions like GLUT1 Deficiency Syndrome, Alzheimer's disease, and other neurodegenerative conditions. Their innovative approach addresses brain hypometabolism, a hallmark of many neurological diseases. Recent major validation includes a $4.2 million investment from the Alzheimer's Drug Discovery Foundation in 2023 to advance their lead compound GP-119 to clinical trials, demonstrating strong scientific credibility and potential market impact.
No open roles listed right now.